References
- LeBlanc TW, Abernethy AP. Patient-reported outcomes in cancer care – hearing the patient voice at greater volume. Nat Rev Clin Oncol. 2017;14:763–772.
- Basch E, Deal AM, Dueck AC, et al. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA. 2017;318:197–198.
- Basch E, Reeve BB, Mitchell SA, et al. Development of the National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). JNCI J Natl Cancer Inst. 2014;106. DOI:10.1093/jnci/dju244.
- World Health Organization; GLOBOCAN. Cancer fact sheets: prostate cancer; 2012 [accessed 2017 Dec 19]. Available from: http://globocan.iarc.fr/old/FactSheets/cancers/prostate-new.asp
- Association of the Nordic Cancer Registries. NORDCAN, Kraeftstatistik: Nøgletal og figurer; 2016 [cited 2017 Dec 19]. Available from: http://www-dep.iarc.fr/NORDCAN/DK/StatsFact.asp?cancer=261&country=208
- Professionals S-O. Prostate Cancer. Uroweb; 2014 [accessed 2017 Dec 19]. Available from: http://uroweb.org/guideline/prostate-cancer/
- U.S. Food & Drug Administration. Highlights of prescribing information. Xofigo; 2013 [cited 2017 Dec 19]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203971lbl.pdf
- U.S. Food & Drug Administration. Highlights of prescribing information. Jevtana; 2010 [cited 2017 Dec 19]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/201023lbl.pdf
- U.S. Food & Drug Administration. Highlights of prescribing information. Taxotere; 2010 [cited 2017 Dec 19]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020449s059lbl.pdf
- European Medicines Agency. EPAR product information; 2017 [cited 2017 Dec 19]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002018/WC500104764.pdf
- European Medicines Agency. EPAR product information. Xofigo; 2016 [cited 2017 Dec 19]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002653/WC500156172.pdf
- European Medicines Agency. EPAR product information. Taxotere; 2017 [cited 2017 Dec 19]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000073/WC500035264.pdf
- Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–1512.
- de Bono JS, Oudard S, Ozguroglu M, et al; TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147–1154.
- Parker CC, Pascoe S, Chodacki A, et al. A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. Eur Urol. 2013;63:189–197.
- Baeksted C, Pappot H, Nissen A, et al. Feasibility and acceptability of electronic symptom surveillance with clinician feedback using the Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Danish prostate cancer patients. J Patient Rep Outcomes. 2017;1:1.
- Baeksted C, Nissen A, Pappot H, et al. Danish translation and linguistic validation of the US National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). J Pain Symptom Manage. 2016;52:292–297.
- Johnson C, Aaronson N, Blazeby JM, et al. Guidelines for developing questionnaire modules. Eortc Quality of Life GROUP; 2011.